Basit öğe kaydını göster

dc.contributor.authorEsin, Ece
dc.contributor.authorYildiz, Ferah
dc.contributor.authorLacin, Sahin
dc.contributor.authorKarakas, Yusuf
dc.contributor.authorGültekin, Melis
dc.contributor.authorDizdar, Ömer
dc.contributor.authorYalçin, Şuayib
dc.date.accessioned2019-12-10T11:30:51Z
dc.date.available2019-12-10T11:30:51Z
dc.date.issued2018
dc.identifier.issn1300-4948
dc.identifier.urihttps://doi.org/10.5152/tjg.2018.17660
dc.identifier.urihttp://hdl.handle.net/11655/15819
dc.description.abstractBackground/Aims: An organ preservation approach using chemoradiotherapy has been established for anal cancer. This retrospective cohort study aimed to define the clinico-demographic characteristics and outcomes of cases of human immunodeficiency virus (HIV)-negative anal carcinoma during a period of 20 years in a single comprehensive cancer institute. Materials and Methods: This was a single-center retrospective cohort study of patients who were treated between January 1995 and January 2015. The primary outcome measures that were investigated included overall survival (OS), progression-free survival (PFS), colostomy rates, and colostomy-free survival (CFS). Results: A total of 28 patients who were principally treated with standard 5-fluorouracil + mitomycin combination chemoradiotherapy were eligible for analysis. The 3- and 5-year PFS rates were 92.4% and 63%, respectively. The lower T stage was found to be associated with a prolonged PFS (p=0.001). The 3- and 5-year CFS rates were 84.3% and 74.9%, respectively. A longer CFS was observed with lower T stages (p=0.05). At the last follow-up, 75% of the patients with anal cancer were alive, and 71.4% of the patients were disease free. The median OS was not reached with a median follow-up of 54 months (range, 6-115 months). The 3- and 5-year OS rates were 82% and 71.1%, respectively. No late toxicity was observed during the follow-up period. Discussion: The short- and long-term prognoses of HIV-negative patients with anal squamous cell carcinoma were good, and low-grade toxicity was rare, thereby demonstrating that these patients can be successfully treated in a real-life setting with favorable outcomes.
dc.language.isoen
dc.publisherAves
dc.relation.isversionof10.5152/tjg.2018.17660
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectGastroenterology & Hepatology
dc.titleReal World Survival Data of A Rare Malignancy: Anal Cancer Results in Hiv Negative Patients From Turkey
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.relation.journalTurkish Journal Of Gastroenterology
dc.contributor.departmentRadyasyon Onkolojisi
dc.identifier.volume29
dc.identifier.issue4
dc.identifier.startpage411
dc.identifier.endpage418
dc.description.indexWoS


Bu öğenin dosyaları:

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster